Is it Flu or is it COVID-19?
With the new BD Veritor™ SARS-CoV-2 and Flu A+B test* now you know.
1 sample. 1 test. 3 unambiguous results.
With a concerning new COVID-19 variant spreading and flu cases on the rise,†
now is
no time for uncertainty. But the fact remains, symptoms for common respiratory conditions, including COVID-19, are nearly identical. Fortunately, the BD Veritor™ Plus System offers a SARS-CoV-2 and Flu A+B assay that streamlines the testing process, providing a reliable diagnosis from a single patient sample in just 15 minutes.
As simple as Veritor™ & Go. Find out more about the BD Veritor™ Plus System and combined testing for COVID-19 and Flu A+B by visiting
BDVeritor.com
†Centers for Disease Control and Prevention Weekly U.S. Infl uenza Surveillance Report
*The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 & Flu A+B is intended for the qualitative detection of SARS-CoV-2 and/or infl uenza A and B nucleocapsid antigens directly from anterior nasal swab samples taken from individuals who are suspected of a viral respiratory infection consistent with COVID-19 by a healthcare provider, within the fi rst six days of symptom onset • This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories. • This product has been authorized only for the detection of proteins from SARS-CoV-2, infl uenza A and infl uenza B, not for any other viruses or pathogens. • This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
• Testing is limited to laboratories certifi ed under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certifi cate of Waiver, Certifi cate of Compliance, or Certifi cate of Accreditation.
BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663
BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and Company or its affiliates. © 2021 BD. All rights reserved.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
